---
layout: post
title: "药明康德涨超9%！医药股迎来大爆发 业绩高增标的获青睐 疫情防治线或成亮点"
date: 2022-03-10 13:25:00 +0800
categories: emnews
tags: 东财滚动新闻
---
> 近日，多家上市公司披露1至2月经营情况，业绩大幅超市场预期，相关个股也迎来大幅反弹，有机构认为，今年医药板块进入疫情后常态发展阶段，因此一季报高增长或将成为先导性指标。

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.603259&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" alt="K图 603259_0" data-code="K 603259|1|1" data-code2="K 603259|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" border="0" /></p><!-- EM_StockImg_End --><p>今日(3月10日)，医药相关板块集体活跃，<span id="bk_90.BK1042"><a href="http://quote.eastmoney.com/unify/r/90.BK1042" class="keytip" data-code="90,BK1042">医药商业</a></span><span id="bkquote_90.BK1042"></span>、CRO概念、<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>、生物医药等板块均大幅走强。个股方面，截止午间收盘，<span id="stock_0.301015"><a href="http://quote.eastmoney.com/unify/r/0.301015" class="keytip" data-code="0,301015">百洋医药</a></span><span id="quote_0.301015"></span>获20cm涨停，<span id="stock_1.600713"><a href="http://quote.eastmoney.com/unify/r/1.600713" class="keytip" data-code="1,600713">南京医药</a></span><span id="quote_1.600713"></span>、<span id="stock_1.600829"><a href="http://quote.eastmoney.com/unify/r/1.600829" class="keytip" data-code="1,600829">人民同泰</a></span><span id="quote_1.600829"></span>、<span id="stock_0.002788"><a href="http://quote.eastmoney.com/unify/r/0.002788" class="keytip" data-code="0,002788">鹭燕医药</a></span><span id="quote_0.002788"></span>、<span id="stock_1.600056"><a href="http://quote.eastmoney.com/unify/r/1.600056" class="keytip" data-code="1,600056">中国医药</a></span><span id="quote_1.600056"></span>、<span id="stock_0.002864"><a href="http://quote.eastmoney.com/unify/r/0.002864" class="keytip" data-code="0,002864">盘龙药业</a></span><span id="quote_0.002864"></span>、<span id="stock_0.002907"><a href="http://quote.eastmoney.com/unify/r/0.002907" class="keytip" data-code="0,002907">华森制药</a></span><span id="quote_0.002907"></span>等多股涨停，其中，龙头股<span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>高开高走，大涨超9%，近期持续活跃的<span web="1" href="http://quote.eastmoney.com/unify/r/1.600056" class="em_stock_key_common" data-code="1,600056">中国医药</span>一字涨停，录得7天5板。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D24993236478261323145_w692h317.jpg" emheight="266" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" width="580" /></center><p> 注：<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1042" class="em_stock_key_common" data-code="90,BK1042">医药商业</span>板块今日表现(截止3月10日午间收盘)</p><p><strong><span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>大涨超9%，高增标的受市场青睐</strong></p><p>昨日晚间，<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>公布今年1至2月主要经营数据，其在手订单和销售收入同比增速均超过65%，创下历史新高，公司预计2022年第一季度收入同比增长将达到65-68%。展望全年，公司收入同比增长有望达到65-70%。<span id="stock_1.600918"><a href="http://quote.eastmoney.com/unify/r/1.600918" class="keytip" data-code="1,600918">中泰证券</a></span><span id="quote_1.600918"></span>指出，公司所处赛道高景气，“一体化、端到端”策略有望夯实竞争壁垒，驱动公司长期快速增长。受经营数据和<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>提振，<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>今日高开高走，截止今日(3月10日)午间，当日涨幅超9%，股价也修复至百元关口上方。</p><p>近日，多家上市公司公布1至2月的经营数据，不少企业的业绩增速超市场预期，股价也迎来大幅反弹，随着一季报行情逐步到来，市场也逐步开始布局和关注业绩高增的企业。<span id="Info.116.01456"><a href="http://quote.eastmoney.com/unify/r/116.01456" class="keytip" data-code="116,01456">国联证券</a></span>指出，过去两年市场随疫情波动较大，<strong>2022年开始医药板块进入疫情后常态发展阶段，因此一季报高增长或将成为先导性指标</strong>。3月进入年季报密集披露期，市场更加关注年季报超预期的标的，一季报比年报更为重要，筛选估值处于相对底部且业绩高增长的公司，有望带来超额收益。</p><p>配置思路方面，<span id="stock_1.601555"><a href="http://quote.eastmoney.com/unify/r/1.601555" class="keytip" data-code="1,601555">东吴证券</a></span><span id="quote_1.601555"></span>指出，结合一季报，主流医药公司都较好，建议从两个策略选择标的：1)<strong>关注2022Q1高增速、全年高景气度个股，即具备较强业绩弹性的高成长个股，重点推荐关注<span id="stock_0.301096"><a href="http://quote.eastmoney.com/unify/r/0.301096" class="keytip" data-code="0,301096">百诚医药</a></span><span id="quote_0.301096"></span>、<span id="stock_0.301080"><a href="http://quote.eastmoney.com/unify/r/0.301080" class="keytip" data-code="0,301080">百普赛斯</a></span><span id="quote_0.301080"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>、<span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span></strong>；2)关注低估值的个股，重点推荐关注<span id="stock_0.300636"><a href="http://quote.eastmoney.com/unify/r/0.300636" class="keytip" data-code="0,300636">同和药业</a></span><span id="quote_0.300636"></span>、<span id="stock_0.000661"><a href="http://quote.eastmoney.com/unify/r/0.000661" class="keytip" data-code="0,000661">长春高新</a></span><span id="quote_0.000661"></span>、<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>，建议关注<span id="Info.116.06078"><a href="http://quote.eastmoney.com/unify/r/116.06078" class="keytip" data-code="116,06078">海吉亚医疗</a></span>、<span id="stock_1.603987"><a href="http://quote.eastmoney.com/unify/r/1.603987" class="keytip" data-code="1,603987">康德莱</a></span><span id="quote_1.603987"></span>。</p><p><strong>板块进入后疫情阶段，防治线或仍是亮点</strong></p><p>在今日众多走强的医药股中，<span web="1" href="http://quote.eastmoney.com/unify/r/1.600056" class="em_stock_key_common" data-code="1,600056">中国医药</span>近日表现持续活跃，股价自3月以来开启火箭式上涨，截止今日(3月10日)午间收盘，本月累计上涨72.8%。消息面，中国医药近日<span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>，公司与<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>公司签订协议，将在协议期内(2022年度)负责<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>公司新冠病毒治疗药物在中国大陆市场的商业运营。不过，公司也表示预计相关业务规模占公司整体业务量比重较小，对公司近期经营业绩无重大影响。</p><center><img src="https://dfscdn.dfcfw.com/download/D25061689641305340359_w692h409.jpg" emheight="343" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" width="580" /></center><p>目前，新冠疫情影响持续，防疫工作走向常态化，“疫苗+检测+治疗药”闭环逐步形成。<span id="stock_1.601162"><a href="http://quote.eastmoney.com/unify/r/1.601162" class="keytip" data-code="1,601162">天风证券</a></span><span id="quote_1.601162"></span>认为，新冠疫情预计中长期与人类共存，疫情走向不确定因素较高，建议从三个维度筛选主题投资机会：<strong>1)需求持续性好，2)竞争格局较优，3)传统业务具备估值一定支撑</strong>。建议关注相关标的：</p><p>1)新冠抗原检测：<strong><span id="stock_1.688298"><a href="http://quote.eastmoney.com/unify/r/1.688298" class="keytip" data-code="1,688298">东方生物</a></span><span id="quote_1.688298"></span>、<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>、<span id="stock_1.688075"><a href="http://quote.eastmoney.com/unify/r/1.688075" class="keytip" data-code="1,688075">安旭生物</a></span><span id="quote_1.688075"></span>、<span id="stock_1.688767"><a href="http://quote.eastmoney.com/unify/r/1.688767" class="keytip" data-code="1,688767">博拓生物</a></span><span id="quote_1.688767"></span>、<span id="stock_1.688606"><a href="http://quote.eastmoney.com/unify/r/1.688606" class="keytip" data-code="1,688606">奥泰生物</a></span><span id="quote_1.688606"></span></strong>；</p><p>2)疫苗加强针：<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、康希诺、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span></strong>；</p><p>3)新冠药：<strong><span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>、<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span></strong>；</p><p>4)CDMO供应链：<strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span></strong>。</p><p class="em_media">（文章来源：财联社）</p>

<http://finance.eastmoney.com/news/1344,202203102304553278.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)